A Phase I, Open-label, Non-randomized Study to Characterize the Impact of Dietary Modification on Inavolisib Associated Hyperglycemia and to Assess the CYP3A4 Induction Potential of Inavolisib using Midazolam as a Probe Substrate in Patients with Incurable Metastatic Solid Tumors Previously Treated with Multiple (≥2) Lines of Therapy